Jeffrey Clarke

5.0k total citations · 2 hit papers
88 papers, 3.2k citations indexed

About

Jeffrey Clarke is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jeffrey Clarke has authored 88 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 46 papers in Pulmonary and Respiratory Medicine and 15 papers in Molecular Biology. Recurrent topics in Jeffrey Clarke's work include Lung Cancer Treatments and Mutations (29 papers), Cancer Immunotherapy and Biomarkers (28 papers) and Lung Cancer Research Studies (17 papers). Jeffrey Clarke is often cited by papers focused on Lung Cancer Treatments and Mutations (29 papers), Cancer Immunotherapy and Biomarkers (28 papers) and Lung Cancer Research Studies (17 papers). Jeffrey Clarke collaborates with scholars based in United States, Canada and Spain. Jeffrey Clarke's co-authors include Herbert I. Hurwitz, Mark N. Levine, Edward P. Balaban, Charles W. Francis, Sandra L. Wong, Nigel S. Key, Gary H. Lyman, Anna Falanga, Juan I. Arcelus and Nicole M. Kuderer and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jeffrey Clarke

85 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014

2015 968 citations Gary H. Lyman, Kari Bohlke et al. Journal of Clinical Oncology profile →
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

2013 544 citations Gary H. Lyman, Alok A. Khorana et al. Journal of Clinical Oncology profile →

Peers

Jeffrey Clarke

ONCOL

PRM

CCM

William D. Boswell United States

Alessandra Biasiolo Italy

Jan–Dirk Studt Switzerland

Manuel Carção Canada

Otto M. van Delden Netherlands

James T. Bui United States

Baruch Brenner Israel

Luca Castagna Italy

Sean M. Devlin United States

J. Solà Spain

William D. Boswell United States

Jeffrey Clarke

213 ×0.2

1.2k ×1.2

ONCOL

706 ×0.8

PRM

228 ×0.3

CCM

431 ×0.8

Citations per year, relative to Jeffrey Clarke Jeffrey Clarke (= 1×) peers William D. Boswell

Countries citing papers authored by Jeffrey Clarke

Since Specialization

Citations

This map shows the geographic impact of Jeffrey Clarke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Clarke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Clarke more than expected).

Fields of papers citing papers by Jeffrey Clarke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Clarke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Clarke. The network helps show where Jeffrey Clarke may publish in the future.

Co-authorship network of co-authors of Jeffrey Clarke

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Clarke. A scholar is included among the top collaborators of Jeffrey Clarke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Clarke. Jeffrey Clarke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Clarke, Jeffrey, George R. Simon, Hirva Mamdani, et al.. (2025). Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial. Nature Communications. 16(1). 93–93. 7 indexed citations

Makarova, Anastasia A., et al.. (2024). Integrated genomic and transcriptomic characterization of neuroendocrine carcinomas for improved treatment decision-making.. Journal of Clinical Oncology. 42(16_suppl). e15138–e15138.

Li, Bob T., Jeffrey Clarke, Enriqueta Felip, et al.. (2024). Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial.. Journal of Clinical Oncology. 42(16_suppl). 8512–8512. 8 indexed citations

Yang, Zhenchun, Clare Meernik, Yadurshini Raveendran, et al.. (2024). Neighborhood-level socioeconomic disparities in Radon testing in North Carolina from 2010 to 2020. Journal of Environmental Radioactivity. 277. 107460–107460.

Wang, X., Erin M. Bertino, Scott Antonia, et al.. (2023). A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations. ESMO Open. 8(2). 101183–101183. 12 indexed citations

Aggen, David H., David S. Hong, Jeffrey Clarke, et al.. (2023). Preliminary clinical outcomes of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced urothelial cancer.. Journal of Clinical Oncology. 41(6_suppl). 517–517. 1 indexed citations

Clarke, Jeffrey, Enriqueta Felip, B.T. Li, et al.. (2023). MA06.05 CodeBreaK 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NSCLC. Journal of Thoracic Oncology. 18(11). S118–S119. 12 indexed citations

Gupta, Anjali, Jessica Y. Islam, Ashwini Joshi, et al.. (2023). Socioeconomic disparities in immunotherapy use among advanced-stage non-small cell lung cancer patients: analysis of the National Cancer Database. Scientific Reports. 13(1). 8190–8190. 12 indexed citations

Moore, Kathleen N., Adam Asch, Víctor Moreno, et al.. (2022). 2022-LBA-414-ESGO Preliminary clinical outcome of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced epithelial ovarian cancer. International Journal of Gynecological Cancer. 32. A472–A473. 1 indexed citations

10.

Rottey, Sylvie, Jeffrey Clarke, Kyaw Aung, et al.. (2022). Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors. EUR Research Repository (Erasmus University Rotterdam). 40 indexed citations

11.

Shen, Erica, Amanda E.D. Van Swearingen, Ketan R. Bulsara, et al.. (2022). A Need for More Molecular Profiling in Brain Metastases. Frontiers in Oncology. 11. 785064–785064. 3 indexed citations

12.

Deveaux, April, Tyler A. Allen, Muthana Al Abo, et al.. (2021). RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry. Lung Cancer. 153. 90–98. 5 indexed citations

13.

Sacher, Adrian G., Xiuning Le, Robin Cornelissen, et al.. (2021). 36MO Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer. Annals of Oncology. 32. S15–S15. 19 indexed citations

14.

Deng, Wei, Hongliang Liu, Sheng Luo, et al.. (2020). APOBGenotypes andCDH13Haplotypes in the Cholesterol-Related Pathway Genes Predict Non–Small Cell Lung Cancer Survival. Cancer Epidemiology Biomarkers & Prevention. 29(6). 1204–1213. 10 indexed citations

15.

Moravan, Michael J., Peter E. Fecci, Carey K. Anders, et al.. (2020). Current multidisciplinary management of brain metastases. Cancer. 126(7). 1390–1406. 72 indexed citations

16.

Yi, John S., Neal Ready, Patrick Healy, et al.. (2017). Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab. Clinical Cancer Research. 23(24). 7474–7482. 62 indexed citations

17.

Lyman, Gary H., Kari Bohlke, Alok A. Khorana, et al.. (2015). Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. Journal of Clinical Oncology. 33(6). 654–656. 968 indexed citations breakdown →

18.

Clarke, Jeffrey, Herbert I. Hurwitz, & Fatima Rangwala. (2014). Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: A clinician’s perspective. Cancer Treatment Reviews. 40(9). 1065–1072. 12 indexed citations

19.

Clarke, Jeffrey & Herbert I. Hurwitz. (2013). Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opinion on Biological Therapy. 13(8). 1187–1196. 103 indexed citations

20.

Clarke, Jeffrey & Herbert I. Hurwitz. (2012). Ziv-aflibercept: binding to more than VEGF-A—does more matter?. Nature Reviews Clinical Oncology. 10(1). 10–11. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact